As COVID-19 continues to disrupt clinical research, the consequences are poised to be devastating for sponsors, physicians, patients, and worldwide health. Elligo Health Research® is uniquely situated and experienced to support the continuation of effective clinical research in this new era. From effective mitigation strategies for data integrity, to technological solutions that support decentralized and hybrid trial models as well as an understanding of the real-world needs of sponsors, physicians, and patients, Elligo can provide a successful model for restarting existing trials and beginning clinical research successfully. Read more in our latest white paper.
White Paper